Recently, PanTai Biotechnology (Zhejiang) Co., Ltd. (hereinafter referred to as “PanTai Bio”) announced the completion of a Series A financing round of tens of millions of RMB, exclusively invested by YuanSheng Venture Capital, with QuShi Capital acting as the exclusive financial advisor. The funds raised in this round will be primarily used to support the company’s continued R&D and market expansion on its flow cytometry technology platform, providing clinical patients with comprehensive solutions for precise immune function assessment.
Founded in 2017, PanTai Bio is committed to becoming a globally leading technology company in precise assessment of human immune system function. Leveraging flow cytometry technology, the company continuously develops innovative flow cytometry reagents and instruments that better meet clinical needs, offering comprehensive solutions for precise immune status assessment in various medical scenarios such as infectious diseases, autoimmune disorders, and oncology. Thanks to the deep technical expertise of its core founding team and the relentless efforts of its R&D team, the company has progressed rapidly. It now holds more than twenty core invention patents and has successfully developed multiple innovative flow cytometry reagents and instruments.
Beijing Caihe Law Firm was responsible for conducting Freedom to Operate (FTO) patent infringement risk searches and analysis in this financing round.
